SRES-704-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S2109; text: CR S2135-2136)
Sponsored by Chuck Grassley (R-IA)
What it does
This resolution expresses the Senate's support for the mission and goals of National Fentanyl Awareness Day in 2026. It does not create any new law, program, or funding — it is a symbolic, non-binding statement encouraging public awareness of the dangers of fake or counterfeit fentanyl pills, particularly their impact on families and young people. It was passed by unanimous consent.
Who benefits
Advocacy organizations focused on fentanyl and opioid awareness may gain visibility and a degree of congressional endorsement. Families who have lost members to fentanyl-related overdoses may find symbolic recognition of their cause. Public health communicators and educators working on drug awareness campaigns could point to the resolution as congressional backing. Young people, to the extent that increased awareness reduces exposure to counterfeit pills, are indirect potential beneficiaries.
Who is hurt
No group is directly harmed by this resolution. Critics of symbolic legislation more broadly may argue that non-binding resolutions consume legislative time without producing measurable policy outcomes. There are no direct regulatory, financial, or legal burdens imposed on any individual or group.
Supporters argue
Supporters argue that fentanyl is now the leading cause of death for Americans aged 18–45, with the CDC reporting over 70,000 fentanyl-involved overdose deaths annually, and that counterfeit pills — often indistinguishable from legitimate medications — are a primary vector. They contend that congressional endorsement of awareness efforts amplifies public health messaging at no cost, and that raising awareness among young people and families can reduce the number of accidental exposures and deaths.
Opponents argue
Opponents argue that symbolic resolutions without accompanying funding, enforcement mechanisms, or policy changes do little to address the structural drivers of the fentanyl crisis, such as supply chain interdiction gaps or treatment access shortfalls. They contend that congressional action on awareness days may create the appearance of progress while displacing attention from substantive legislative solutions, and that the measurable public health impact of a non-binding resolution is negligible.